INB4: KEI general comment on the Zero Draft

On 28 February 2023, Knowledge Ecology International (KEI) delivered the following statement on the zero draft prepared by the Bureau of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention,… Continue Reading

US government files statement of Interest in Arbutus v Moderna case, testing scope of 28 USC 1498(a) government use of patents for acquisition and distribution of COVID 19 vaccines

On February 14, 2023, USDOJ filed a Statement of Interest of the United States, in the patent dispute between Arbutus Biopharma, Genevant Sciences, and Moderna. A copy of the filing is here: arbutus.moderna.USG.statementofinterest This is an important, and while not… Continue Reading

WHO pandemic treaty: Modalities for the negotiations in February/March 2023 (INB4) and April 2023 (INB5)

UPDATED: On 10 February 2023, the Bureau of the WHO Intergovernmental Negotiating Body (INB) circulated to WHO member states a proposal for consideration by the INB regarding modalities for upcoming INB meetings (INB4/5), including the “Zero Draft” and “First Draft”… Continue Reading

KEI Comments Regarding NIH Prospective Exclusive License to Yissum R&D

On February 6, 2023, Knowledge Ecology International submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Small Cell Lung Cancer Subtyping Using Plasma Cell-Free Nucleosomes” (88 FR 3749). The technology was… Continue Reading

EB152 – Constituency statement for Knowledge Ecology International, Health Action International, Public Services International, Oxfam, and World Council of Churches – Strengthening the global architecture for health emergency preparedness, response and resilience

On Tuesday, 31 January 2023, Arianna Schouten delivered this constituency statement on behalf of Knowledge Ecology International, Health Action International, Oxfam, Public Services International, and the World Council of Churches on the following topic: “12.1 – Strengthening WHO preparedness for… Continue Reading

31 January 2023 – Save the Date – Recommendations for the WHO Pandemic Treaty Negotiations

Recommendations for the WHO Pandemic Treaty Negotiations DATE: Tuesday, 31 January 2023 TIME: 17:30 to 19:00 CET LOCATION: Salle II/III, World Council of Churches, Route de Ferney 150 Refreshments will be served from 17:00 BACKGROUND: The WHO Intergovernmental Negotiating Body… Continue Reading

25 Members of Congress Ask HHS Secretary to Act on Xtandi Request

On January 10, 2023, twenty-five Members of Congress sent a letter to HHS Secretary Xavier Becerra urging him to act on the Xtandi request, and to use the Bayh-Dole Act to lower the price of Xtandi (enzalutamide) for US patients.… Continue Reading

Member States of the WHO African Region propose ambitious amendments to the International Health Regulations on intellectual property, licensing, transfer of technology, and know-how

While much attention has been focused on negotiations at the World Health Organization (WHO) on a pandemic treaty, there has been less scrutiny on WHO deliberations on proposed amendments to the International Health Regulations (2005). The reasons are two-fold: 1)… Continue Reading

WHO pandemic treaty negotiations: Walkthrough of conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at its third meeting

On 16 November 2022, the Bureau of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response (INB) released the conceptual zero draft in all six official languages… Continue Reading

NIH responds to Sachs/Love letter on the Xtandi Bayh-Dole safeguards petition, to say, still reviewing

NIH has sent a letter, dated Dec 1, to Robert Sachs and Clare Love, regarding the longstanding petition to HHS to use the federal government’s rights in the patented inventions for enzalutamide, marketed by Astellas in the USA at prices 3 to… Continue Reading